Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Sunnybrook Health Sciences Centre Odette Cancer Centre, Room T2 2075 Bayview Ave., Toronto ON Canada M4N 3M5 Tel: 1-416-480-5248 Fax: 1-416-480-6002 E-mail: [email protected] July 2, 2015 Martin R. Chasen, MD Managing Editor, Current Oncology Department of Oncology, Division of Palliative Care Elisabeth Bruyere Hospital Ottawa, ON K1N 5C8 Tel: 1-613-562-6262 ext. 1265 Email: [email protected] Dear Dr. Chasen, RE: Manuscript entitled “Cross-comparison of cancer drug approvals among international regulatory bodies” We are submitting an article to Current Oncology that answers several important questions about the current state of cancer drug approval processes across the major international regulatory agencies. Our manuscript details the first systematic analysis of cancer drug approvals and underscores the marked differences in cancer drug approval processes between regulatory agencies worldwide, including FDA, European authorities and Health Canada. The results from the study were selected for oral presentation at the Public Health and Economics Session at the 2014 ESMO Congress in Madrid and were among the results shared in the opening press conference for the congress. We anticipate that readers of Current Oncology would benefit from this work and will help the reader better understand the framework of cancer drug approvals and this will also help to create a dialogue amongst clinicians and government agencies to address these findings. We hope that you will find our analysis suitable for Current Oncology and we look forward to hearing back from you. Sincerely, Sunil Verma, MD, FRCSC Medical Oncologist Sunnybrook Odette Cancer Centre, Toronto ON Assistant Professor, University of Toronto